Vergote, Ignace
Schilder, Russell J.
Pippitt, Charles H. Jr.
Wong, Shirley
Gordon, Alan N.
Scudder, Sidney
Kridelka, Frederic
Dirix, Luc
Leach, Joseph W.
Ananda, Sumitra
Nanayakkara, Nuwan
Melara, Rebeca
Bass, Michael B.
Litten, Jason
Adewoye, Henry
Wenham, Robert M.
Clinical trials referenced in this document:
Documents that mention this clinical trial
A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer
https://doi.org/10.1016/j.ygyno.2014.07.003
Documents that mention this clinical trial
A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer
https://doi.org/10.1016/j.ygyno.2014.07.003
Targeting the hallmarks of ovarian cancer: The big picture
https://doi.org/10.1016/j.ygyno.2016.03.037
Funding for this research was provided by:
Amgen
This article is maintained by: Elsevier
Article Title: A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer
Journal Title: Gynecologic Oncology
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.ygyno.2014.07.003
Content Type: article
Copyright: Copyright © 2014 Elsevier Inc. All rights reserved.